The results of a randomized phase III trial show paclitaxel beat two newer chemotherapies, nab-paclitaxel and ixabepilone in the treatment of metastatic breast cancer patients who have not had prior systemic therapies.
The idea of adding the targeted EGFR inhibitor cetuximab to standard chemotherapy took a hit, as results from the SELECT phase III trial showed no improvement in efficacy when cetuximab was combined with pemetrexed in patients with recurrent or progressive non–small-cell lung cancer.
Final results of the PARAMOUNT study in non-squamous non–small-cell lung cancer confirmed improved survival with continuation pemetrexed maintenance therapy.
In patients with advanced NSCLC and without any mutation in the EGFR gene, docetaxel provides significantly improved progression-free survival compared to erlotinib, according to a phase III randomized trial.
ASCO: MEK Inhibitors—Alone or Paired With a BRAF Inhibitor—Increase Options, Benefits for Patients With BRAF-Mutated Advanced Melanoma
At the ASCO annual meeting, researchers presented persuasive evidence that a new class of targeted agents—MEK inhibitors—may warrant inclusion in the growing armamentarium for patients with advanced BRAF-mutated melanoma.
Women with metastatic HER2-positive breast cancer treated with a taxane-based chemotherapy in combination with trastuzumab as a first-line of treatment have a longer progression-free survival compared to chemotherapy in combination with lapatinib (Tykerb)
ASCO: Phase II/III Data Establish Dabrafenib as Second BRAF Inhibitor With Proven Efficacy in Metastatic Melanoma
Data from the phase III BREAK-3 and the phase II BREAK-MB trials of dabrafenib establish the drug as the second BRAF inhibitor for BRAF V600E-mutated melanoma.
Researchers reported results of an international phase III trial showing that intermittent hormonal therapy is less effective than continuous therapy in prostate cancer with minimal disease.
Patients with EGFR mutation-positive lung cancer had improved progression-free survival and better quality of life with new drug afatinib than with standard chemotherapy, according to results from a large phase III trial.
The class of agents that target the Programmed Death 1 (PD-1) pathway was described at ASCO as “likely the most exciting new agents recently developed in melanoma.”